Pharmacokinetics of Tacrolimus in Pregnant Solid‐Organ Transplant Recipients: A Retrospective Study
Authors:
Open Access
- 4 January 2024
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 64 (4) , 428-436
Abstract
Data on the pharmacokinetics of tacrolimus during pregnancy are limited. Therefore, the aim of this retrospective study was to characterize the whole‐blood pharmacokinetics of tacrolimus throughout pregnancy. In this single‐center retrospective cohort study, whole‐blood tacrolimus trough concentrations corrected for the dose (concentration‐to‐dose [C/D] ratios) were compared before, monthly during, and after pregnancy in kidney, liver, and lung transplant recipients who became pregnant and gave birth between 2000 and 2022. Descriptive statistics and linear mixed models were used to characterize changes in tacrolimus C/D ratios before, during, and after pregnancy. The total study population included 46 pregnancies (31 pregnant women). Nineteen, 21, and 6 pregnancies were following kidney, liver, and lung transplantation, respectively. Immediate‐release or extended‐release formulations were used in 54.5% and 45.5% of the women, respectively. Tacrolimus C/D ratios significantly (P < .001) decreased (−48%) compared to the prepregnancy state at 7 months of pregnancy. These ratios recovered within 3 months postpartum (P = .002). C/D ratios tended to be lower during treatment with an extended‐release formulation than with an immediate‐release formulation (P = .071). Transplantation type did not significantly affect C/D ratios during pregnancy (P = .873). In conclusion, we found that tacrolimus whole‐blood pharmacokinetics change throughout pregnancy, with the lowest C/D ratios (48% decrease) in the 7th month of pregnancy. In general, the decrease in C/D ratios seems to stabilize from month 4 onward compared to prepregnancy.Keywords
This publication has 26 references indexed in Scilit:
- Pregnancy After Kidney Transplantation: Outcomes, Tacrolimus Doses, and Trough LevelsTransplantation Proceedings, 2015
- The optimal therapy of calcineurin inhibitors for pregnancy in kidney transplantationClinical Transplantation, 2015
- Tacrolimus placental transfer at delivery and neonatal exposure through breast milkBritish Journal of Clinical Pharmacology, 2013
- Interpreting Tacrolimus Concentrations During Pregnancy and PostpartumTransplantation, 2013
- Pharmacokinetics of Tacrolimus During PregnancyTherapeutic Drug Monitoring, 2012
- Robust, High-Throughput LC-MS/MS Method for Therapeutic Drug Monitoring of Cyclosporine, Tacrolimus, Everolimus, and Sirolimus in Whole BloodTherapeutic Drug Monitoring, 2009
- Influence of CYP3A5 Genetic Polymorphism on Tacrolimus Daily Dose Requirements and Acute Rejection in Renal Graft RecipientsBasic & Clinical Pharmacology & Toxicology, 2008
- Comparative Clinical Pharmacokinetics of Tacrolimus in Paediatric and Adult PatientsClinical Pharmacokinetics, 2001
- A successful pregnancy in a kidney recipient with tacrolimus (Prograf, FK 506) therapy.Nephrology Dialysis Transplantation, 1998
- FK506‐induced neurotoxicity in liver transplantationAnnals of Neurology, 1994